Hepatitis B virus infection and its treatment in Eastern Ethiopia

doi:10.4254/wjh.v17.i1.99209

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (67)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

Sum=60

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=2

Jan 27, 2025 (publication date) through Jan 8, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Hepatol. Jan 27, 2025; 17(1): 99209
Published online Jan 27, 2025. doi: 10.4254/wjh.v17.i1.99209

Hepatitis B virus infection and its treatment in Eastern Ethiopia

Tatsuo Kanda, Reina Sasaki-Tanaka, Atsunori Tsuchiya, Shuji Terai

Tatsuo Kanda, Division of Gastroenterology and Hepatology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma 949-7302, Niigata, Japan

Tatsuo Kanda, Reina Sasaki-Tanaka, Atsunori Tsuchiya, Shuji Terai, Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan

Author contributions: Kanda T and Sasaki-Tanaka R designed the overall concept and outline of the manuscript, and wrote the paper; Kanda T, Sasaki-Tanaka R, Tsuchiya A, and Terai S contributed critical revision of the manuscript for important intellectual content.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Tatsuo Kanda, MD, PhD, Professor, Division of Gastroenterology and Hepatology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, 4132 Urasa, Minamiuonuma 949-7302, Niigata, Japan. kandatatsuo@gmail.com

Received: July 17, 2024
Revised: November 21, 2024
Accepted: December 17, 2024
Published online: January 27, 2025
Processing time: 172 Days and 23.5 Hours

Core Tip

Core Tip: To eliminate hepatitis B virus (HBV) infection worldwide by 2030, it is important to determine the actual status of HBV infection in Ethiopia, whose population was estimated 12300000 persons in 2022. At least 10.5% of blood samples from patients in Ethiopia were positive for the HBV surface antigen. In Eastern Ethiopia, HBV surface antigen-positive patients with cirrhosis appeared to be HBV e antigen-positive and had a higher viral load. Tenofovir disoproxil fumarate is effective for the suppression of HBV DNA in these patients. HBV vaccination and the educational programs for Health Science students that provide practical strategies could also reduce HBV infection in Eastern Ethiopia.